310 related articles for article (PubMed ID: 18264006)
1. Increased incidence of acute kidney injury with aprotinin use during cardiac surgery detected with urinary NGAL.
Wagener G; Gubitosa G; Wang S; Borregaard N; Kim M; Lee HT
Am J Nephrol; 2008; 28(4):576-82. PubMed ID: 18264006
[TBL] [Abstract][Full Text] [Related]
2. Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.
Maslow AD; Chaudrey A; Bert A; Schwartz C; Singh A
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):6-15. PubMed ID: 18249324
[TBL] [Abstract][Full Text] [Related]
3. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery?
Kincaid EH; Ashburn DA; Hoyle JR; Reichert MG; Hammon JW; Kon ND
Ann Thorac Surg; 2005 Oct; 80(4):1388-93; discussion 1393. PubMed ID: 16181876
[TBL] [Abstract][Full Text] [Related]
4. The association of renal dysfunction and the use of aprotinin in patients undergoing congenital cardiac surgery requiring cardiopulmonary bypass.
Manrique A; Jooste EH; Kuch BA; Lichtenstein SE; Morell V; Munoz R; Ellis D; Davis PJ
Anesth Analg; 2009 Jul; 109(1):45-52. PubMed ID: 19535694
[TBL] [Abstract][Full Text] [Related]
5. The effect of aprotinin on outcome after coronary-artery bypass grafting.
Shaw AD; Stafford-Smith M; White WD; Phillips-Bute B; Swaminathan M; Milano C; Welsby IJ; Aronson S; Mathew JP; Peterson ED; Newman MF
N Engl J Med; 2008 Feb; 358(8):784-93. PubMed ID: 18287601
[TBL] [Abstract][Full Text] [Related]
6. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery.
Karkouti K; Wijeysundera DN; Yau TM; McCluskey SA; Tait G; Beattie WS
Anesth Analg; 2010 Jan; 110(1):21-9. PubMed ID: 19910626
[TBL] [Abstract][Full Text] [Related]
7. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery.
Wagener G; Gubitosa G; Wang S; Borregaard N; Kim M; Lee HT
Am J Kidney Dis; 2008 Sep; 52(3):425-33. PubMed ID: 18649981
[TBL] [Abstract][Full Text] [Related]
8. Aprotinin in cardiac surgery patients: is the risk worth the benefit?
Stamou SC; Reames MK; Skipper E; Stiegel RM; Nussbaum M; Geller R; Robicsek F; Lobdell KW
Eur J Cardiothorac Surg; 2009 Nov; 36(5):869-75. PubMed ID: 19782574
[TBL] [Abstract][Full Text] [Related]
9. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis.
Guzzetta NA; Evans FM; Rosenberg ES; Fazlollah TM; Baker MJ; Wilson EC; Kaiser AM; Tosone SR; Miller BE
Anesth Analg; 2009 Feb; 108(2):448-55. PubMed ID: 19151271
[TBL] [Abstract][Full Text] [Related]
10. The risk associated with aprotinin in cardiac surgery.
Mangano DT; Tudor IC; Dietzel C; ;
N Engl J Med; 2006 Jan; 354(4):353-65. PubMed ID: 16436767
[TBL] [Abstract][Full Text] [Related]
11. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in non-diabetic patients with stage 2-4 chronic kidney disease.
Malyszko J; Bachorzewska-Gajewska H; Sitniewska E; Malyszko JS; Poniatowski B; Dobrzycki S
Ren Fail; 2008; 30(6):625-8. PubMed ID: 18661413
[TBL] [Abstract][Full Text] [Related]
12. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults.
Haase M; Bellomo R; Devarajan P; Ma Q; Bennett MR; Möckel M; Matalanis G; Dragun D; Haase-Fielitz A
Ann Thorac Surg; 2009 Jul; 88(1):124-30. PubMed ID: 19559209
[TBL] [Abstract][Full Text] [Related]
13. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
14. Aprotinin is safe in pediatric patients undergoing cardiac surgery.
Backer CL; Kelle AM; Stewart RD; Suresh SC; Ali FN; Cohn RA; Seshadri R; Mavroudis C
J Thorac Cardiovasc Surg; 2007 Dec; 134(6):1421-6; discussion 1426-8. PubMed ID: 18023656
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin and renal dysfunction after pediatric cardiac surgery.
Székely A; Sápi E; Breuer T; Kertai MD; Bodor G; Vargha P; Szatmári A
Paediatr Anaesth; 2008 Feb; 18(2):151-9. PubMed ID: 18184247
[TBL] [Abstract][Full Text] [Related]
16. Effect of aprotinin on renal dysfunction in patients undergoing on-pump and off-pump cardiac surgery: a retrospective observational study.
Mouton R; Finch D; Davies I; Binks A; Zacharowski K
Lancet; 2008 Feb; 371(9611):475-82. PubMed ID: 18262039
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effect of aprotinin and ε-aminocaproic acid on renal function in children undergoing cardiac surgery.
Leyvi G; Nelson O; Yedlin A; Pasamba M; Belamarich PF; Nair S; Cohen HW
J Cardiothorac Vasc Anesth; 2011 Jun; 25(3):402-6. PubMed ID: 21419653
[TBL] [Abstract][Full Text] [Related]
18. Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin.
Dietrich W; Busley R; Boulesteix AL
Anesthesiology; 2008 Feb; 108(2):189-98. PubMed ID: 18212563
[TBL] [Abstract][Full Text] [Related]
19. Renal dysfunction in cardiac surgery: identifying potential risk factors.
Barnum JL; Sistino JJ
Perfusion; 2009 Mar; 24(2):139-42. PubMed ID: 19654159
[TBL] [Abstract][Full Text] [Related]
20. Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study.
Jakobsen CJ; Søndergaard F; Hjortdal VE; Johnsen SP
Eur J Cardiothorac Surg; 2009 Nov; 36(5):863-8. PubMed ID: 19782573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
